ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / CAH
COR (70) MCK (85) HLF (64) NUS (53) ⌘ Pro Terminal →

Cardinal Health Inc. (CAH) — RQD Stock Rating Cockpit

$250.48 -0.24% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $250.97

Cardinal Health Inc. (CAH) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (4% profit margin, 30% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate) →
ROARABLE B • BUY Cap $58.14B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CAH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CAH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Cardinal Health Inc. (NYSE: CAH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $250.48 (-0.24% 1D, market cap $58.14B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, CAH ranks #53 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CAH compare to COR and MCK in the Health Care sector?
▼

Within the Health Care sector (Other Pharmaceuticals), CAH carries a Roarable B (73/100 RQD), trailing P/E of 37.2x, gross margin of 3.7%, and ROIC of 29.7%. By comparison, COR (Cencora Inc.) holds a B- grade (70/100 RQD, P/E 40.6x, ROIC 26.8%, cap $63.07B) and MCK (McKesson Corporation) posts a A- grade (85/100 RQD, P/E 24.0x, ROIC 38.6%, cap $114.36B). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while MCK leads on capital efficiency (38.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CAH?
▼

Per CAH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000721371), Cardinal Health Inc. generated $222.58B in revenue (-1.9% YoY), $1.56B in net income, and $1.85B in free cash flow against $58.08B in total assets and $13.59B in total debt. Key quantitative strengths: Strong cash generator (4% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $250.98 (+0.20%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 0.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510073
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk C
Cash (16)Whales (17)SEC (14)Macro (12)CEO (14)
Each axis scored 0–20
12M PRICE TARGET CONE+6.8% Base Target
$316 Bull$267 Base$205 Bear
📬 FREE CAH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CAH)Realized 20D OHLCV Swing Band: ±5%
Deterministic 5-Pillar Attribution (73/100 Composite)
🔍 WHY CAH SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (23% of score)

20D Institutional Volume Accumulation (±5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0.8% FCF Margin ($1.85B FCF) & 3.7% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit12/20 pts (-8 pt drag)

Macro rate sensitivity & RSI-14 (59.1) create a -8 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
65
Grade C+$239.72+7.4% Next Q
Q2 (-2Q)
68
Grade B-$257.55-4.3% Next Q
Q3 (-1Q)
70
Grade B$246.45+1.6% Next Q
Current
73
Grade B$250.48+7.1% Hist 90D α
Trajectory: C+ (65) → B (73)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CAH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 73/100 (B) score, CAH faces multiple-compression risk if 37.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 15.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($238.58) or 200D SMA ($222.54) invalidates the momentum regime and cuts Target Base ($267.39) toward Bear Floor ($205.39).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CAH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CAH Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 73%NO 27%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
59.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
5.16>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
6 / 99-Pt Accounting
52-WEEK LASER RANGE88% OF RANGE
L: $180$250.48H: $260
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (4% profit margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: B+RQD 31 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on CAH

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

29.7% ROIC with 3.7% gross margin and 3.18% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 5.16 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (72)

31/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like CAH
  • ✓Strong cash generator (4% profit margin)—profits are backed by real money, not accounting tricks.
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
  • ✓Company leadership has skin in the game with net positive insider conviction.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CAH Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CAH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +27.11%📐 HORIZONTAL RANGE
2026-11-02O $244.8H $251.1L $244.8C $250.5VOL 1.74M
RES: $259.9SUP: $214.8SMA50: $238.6SMA200: $222.5
$265.4$242.4$219.4$196.3$173.3RES $259.9SUP $214.8$250.52026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CAH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CAH Butterfly Map → + Track CAH →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
28.5%/yr Implied 5Y Growth

vs. -1.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CAH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CAH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CAH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CAH)

Health Care Rank #53 of 1016 ⚔️ COR vs CAH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CAH vs. COR, MCK, HLF, NUS)

Industry: Other Pharmaceuticals (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cardinal Health Inc. (CAH) ranks #53 by composite RQD confidence (73/100, grade B) and #34 by equity capitalization ($58.14B). Within this direct 5-issuer industry benchmark cohort, HLF leads on earnings valuation at 5.9x trailing P/E, while MCK leads on capital efficiency and profitability with 38.6% ROIC and 3.6% gross margin. MCK currently holds the highest overall quantitative score in the immediate peer group at 85/100 (A-) compared with CAH at 73/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CAH ACTIVE
Cardinal Health Inc.
B 73/100 37.2x 3.7% 29.7% -0.24% $58.14B Benchmark Subject
COR
Cencora Inc.
B- 70/100 40.6x 3.6% 26.8% +0.09% $63.07B /cor-vs-cah →
MCK
McKesson Corporation
A- 85/100 24.0x 3.6% 38.6% +1.40% $114.36B /mck-vs-cah →
HLF
Herbalife Ltd.
C 64/100 5.9x 77.9% 34.4% +0.93% $1.36B /hlf-vs-cah →
NUS
Nu Skin Enterprises Inc.
D+ 53/100 — 69.4% 6.7% -0.85% $228.3M /nus-vs-cah →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000721371

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Cardinal Health Inc. (CAH) reported GAAP revenue of $222.58B (-1.9% vs. FY2024 revenue of $226.83B , and +8.6% cumulative change since FY2023) , GAAP net income of $1.56B, operating cash flow of $2.40B, and free cash flow of $1.85B (-43.1% YoY). On the balance sheet, CAH closed FY2025 with $58.08B in total assets against $13.59B in total debt (Altman Z-Score: 5.16, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $222.58B $1.56B $2.40B $1.85B $58.08B $13.59B
FY2024 (FY) 2024-06-30 $226.83B $852.0M $3.76B $3.25B $47.00B $11.00B
FY2023 (FY) 2023-06-30 $204.98B $330.0M $2.84B -$6.38B $245.97B $57.56B

3. CAH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CAH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Cardinal Health Inc. (NYSE: CAH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $250.48 (-0.24% 1D, market cap $58.14B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, CAH ranks #53 in composite RQD confidence.

How does CAH compare to COR and MCK in the Health Care sector?

Within the Health Care sector (Other Pharmaceuticals), CAH carries a Roarable B (73/100 RQD), trailing P/E of 37.2x, gross margin of 3.7%, and ROIC of 29.7%. By comparison, COR (Cencora Inc.) holds a B- grade (70/100 RQD, P/E 40.6x, ROIC 26.8%, cap $63.07B) and MCK (McKesson Corporation) posts a A- grade (85/100 RQD, P/E 24.0x, ROIC 38.6%, cap $114.36B). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while MCK leads on capital efficiency (38.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CAH?

Per CAH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000721371), Cardinal Health Inc. generated $222.58B in revenue (-1.9% YoY), $1.56B in net income, and $1.85B in free cash flow against $58.08B in total assets and $13.59B in total debt. Key quantitative strengths: Strong cash generator (4% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CAH trading relative to its 50-day, 200-day, and 52-week technical levels?

CAH last traded at $250.48 (-0.24% on volume of 1,945,008 shares), positioning the stock +4.99% above its 50-day simple moving average ($238.58) and +12.56% above its 200-day simple moving average ($222.54). Across its 52-week range of $180.45 to $259.84, CAH sits at the 88.2% percentile with a 14-day RSI of 59.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.0% ($237.96 to $263.00).

CAH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CAH stock right now?

Cardinal Health Inc. (CAH) currently earns a Roarable Rating of B (Buy — BUY) with 73/100 RQD Confidence. High-quality cash engine (4% profit margin, 30% return on capital) with steady institutional support.

What is CAH's 12-month price target and RQD AI Jury consensus?

CAH's 12-month base price target is $267.39 (range $205.39 to $315.52), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CAH RQD Cockpit CAH 12M Forecast CAH Earnings & Move CAH Dividends & DRIP CAH Insiders & 13F CAH Whale Options CAH Profit Sankey CAH News & Why
ROARABLE RATING BRIEF • RQD 73/100 (B) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CAH — Cardinal Health Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:10:51Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CAH carries an RQD Score of 73, a letter grade of B, and the verdict label "Roarable Buy — Good Risk/Reward." The five pillars are:

  • Fundamental Cash Engine (16/20): Per the Roarable RQD rating, ROIC is 29.7% and FCF yield is 3.18%. This is the second-strongest pillar and suggests the business generates meaningful returns on capital, though the thin reported margins (see Financial Trend) mean the return profile is driven by capital efficiency rather than high per-dollar profit.
  • Whale 13F Flow (17/20): Per the Roarable RQD rating, this is the highest-scoring pillar, citing institutional accumulation and options positioning. The underlying 13F and options detail is not itemized in the source data, so the score cannot be traced to specific holders.
  • Insider Conviction (14/20): Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. Specific transactions are not itemized in the source data.
  • Macro Regime Fit (12/20): Per the Roarable RQD rating, beta is 0.9 and the pillar reflects sector sensitivity. This is the lowest pillar, indicating the stock's fit with the prevailing macro regime is the least favorable component of the score.
  • Forensic Balance Sheet (14/20): Per the Roarable RQD rating, Altman Z is 5.16, Piotroski F is 6/9, and Debt/Equity is 0.85. These readings point to a balance sheet the rating treats as sound.

Taken together, the score indicates that the stock's strengths are concentrated in capital returns, institutional interest, and balance sheet quality, while its weakest link is macro regime fit. For a prospective investor, the key tradeoff is valuation: per the Market Data section, trailing P/E is 37.2 and EV/EBITDA is 24.5, which means the price already embeds substantial expectations relative to reported earnings. The rating's positive verdict should be read alongside these valuation multiples rather than in isolation. This is an analytical framing, not personalized advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$251.09$58.14B37.234.624.56.740.85%0.9$180.45 - $259.8429.7%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$222578.0M$2275.0M$1561.0MN/A$1850.0M$2777.0M$13591.4M
FY 2024$226827.0M$1243.0M$852.0MN/A$3251.0M$3810.0M$10998.5M
FY 2023$204979.0M$752.0M$330.0MN/A$-6380.1MN/A$57558.1M

Per the SEC financials, net income rose from $330.0M (FY 2023) to $852.0M (FY 2024) and $1561.0M (FY 2025), while revenue moved from $204979.0M to $226827.0M and then $222578.0M. Debt fell from $57558.1M in FY 2023 to $13591.4M in FY 2025. Per the Roarable RQD rating, the Altman Z-Score is 5.16 and the Piotroski F-Score is 6/9, consistent with the forensic balance sheet pillar. Per the Market Data, ROIC is 29.7% while net margin is 0.7%, and the Market Data section does not provide a historical margin series to confirm the trend.

Recent Catalysts & News Wire Analysis

Per the recent news feed, all six items are tagged to CAH with a YELLOW light and MARKET WIRE impact label:

  • Yahoo Finance: "Should Value Investors Buy Cardinal Health (CAH) Stock?"
  • Investor's Business Daily: "IBD Stock Of The Day Tests New Buy Point As Indicators Suggest More Upside"
  • Yahoo Finance: "Cardinal Health (CAH) Laps the Stock Market: Here's Why"
  • The Globe and Mail: "RBC Capital Sticks to Its Buy Rating for Cardinal Health (CAH)"
  • Yahoo Finance: "Reasons to Retain Cardinal Health Stock in Your Portfolio for Now"
  • The Globe and Mail: "Can CAH's Specialty Strength Offset Medical Distribution Challenges in Q1?"

Per the news wire, the headlines reference a buy point, an RBC Buy rating, and "medical distribution challenges in Q1." The news summaries are generic and do not disclose the underlying event details. Risk watch item: the single headline referencing distribution challenges is the only explicit negative signal. Per the Butterfly Supply-Chain Graph, the supply chain is "NONE" and proprietary signals are empty; no proprietary signal is available.

Open Questions

  • What is the specific nature of the "medical distribution challenges" referenced in the Q1 news item, and what is their financial magnitude?
  • Which institutional holders and options positions underlie the 17/20 Whale 13F Flow pillar?
  • Which SEC Form 4 and Congressional PTR transactions drive the 14/20 Insider Conviction pillar?
  • Why is EPS reported as N/A across all three financial periods despite trailing EPS of 6.74?
  • What is the company's revenue and margin breakdown by business line, which the source data does not provide?

CAH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cardinal Health Inc. (CAH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CAH Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CAH Bull vs. Bear Conversation Board — What's Your Call at $250.48?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CAH 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CAH:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $296.29 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CAH (B • RQD 73/100) a Buy at $251.09?

Welcome to the CAH (Cardinal Health Inc.) Roar Pit. Current RQD Composite is 73/100 (Roarable Buy — Good Risk/Reward) in Other Pharmaceuticals. Bulls point to capital efficiency (29.7% ROIC), while bears focus on valuation multiple compression (37.2x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $188.32 (-25.0%)
Spot @ $251.09

Pump the brakes on CAH — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CAH, but look at what you are paying: 37.2x trailing P/E with 3.7% gross margins. Unless Cardinal Health Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $321.40 (+28.0%)
Spot @ $251.09

CAH cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CAH, the market is fixating on short-term headline noise in Other Pharmaceuticals and ignoring the balance sheet and cash flow trajectory. At $251.09 (52-wk range $180.45 - $259.84), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%